Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492943 · ClinicalTrials.gov registry record
To Observe Whether Isoflurane Can Treat COVID-19 Patients
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 35
- Enrollment target
NCT04492943: Completed study, sponsored by Massachusetts General Hospital.
NCT04492943 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04492943 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
This is a blood collection and retrospective data collection study. The investigators plan to assess whether the sedative drug, isoflurane, can treat COVID-19 patients relatively better compared to other sedative drugs given during routine treatment to patients on mechanical ventilation. The investigators will also use nanoneedle biosensors to quickly detect blood IgM/IgG ratio in those patients, and (3) to establish a pre-clinical system to determine the effects of inhalational anesthetics on amounts of SARS-CoV-2 and other viruses, and pneumoniae.
Primary Outcome
Survival outcome will be based on whether the patient either (a) recovers from COVID-19 and is discharged from the hospital or (b) does not recover from COVID-19 and passes away while in the hospital.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2020-06-30 |
What the finished NCT04492943 record still lists
NCT04492943 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04492943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04492943 about?
NCT04492943 is a clinical study titled "To Observe Whether Isoflurane Can Treat COVID-19 Patients". This is a blood collection and retrospective data collection study. The investigators plan to assess whether the sedative drug, isoflurane, can treat COVID-19 patients relatively better compared to other sedative drugs given during routine treatment to patients on mechanical ventilation. The investi...
What is the current status of trial NCT04492943?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2020-04-20. Estimated completion is 2020-06-30.
Who is sponsoring clinical trial NCT04492943?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI